ALT - Altimmune, Inc. Forward P/S Multiple

Graphic logo of Altimmune Corp (ALT)

The estimated forward P/S for Altimmune, Inc. (ALT) reflects the impact of pemvidutide development for obesity treatment and compliance with environmental regulations regarding laboratory emission filtration. The 10376.90 metric confirms the current business valuation, which relies on sustained demand, although it remains dependent on the stability of global supply chains and patent protection amid geopolitical tensions.

ALT Altimmune: Market Cap to Expected Sales Ratio in the range 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Altimmune Pharma (ALT)

- market price and analyst price targets:
Price Chart Altimmune|ALT - Price Target Chart
- market capitalization statistics:
Market Capitalization Altimmune Pharma|ALT - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share Altimmune|ALT - Book Valuation of Business|Market Value to Book Value Ratio altimmune.com|ALT - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Altimmune, Inc.|ALT - Long-Term Debt to Capital|Short-Term Debt to Equity Altimmune, Inc.|ALT - Company Debts|Debt to Book Value Altimmune Pharma|ALT - Amount of Long-Term Liabilities|Company Short-Term Debts Altimmune|Quick Liquidity altimmune.com
- business earnings and investment ratios data:
ALT - Net Income|Expected Profit Altimmune, Inc.|ALT - Price to Earnings Ratio|Projected Price to Earnings Altimmune Corp|ALT - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Altimmune Pharma|ALT - Operating profit before amortization|Net earnings per share (EPS TTM) Altimmune|ALT - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months altimmune.com|ALT - Earnings per share increase in current year|Earnings growth forecast for next year Altimmune, Inc.
- sales volume and revenue indicators:
ALT - Company Gross Revenue|Company Projected Revenue Altimmune|ALT - Market Cap to Revenue Ratio|Forward P/S Multiple Altimmune Pharma
Summary company analytics:Altimmune (ALT)
Product sample of Altimmune, Inc.

The forward P/S ratio assesses the market value of Altimmune, Inc. (ALT) relative to expected sales volume, determining demand resilience and the risk of a "value trap" during price declines. Analyzing the expected price-to-sales ratio allows for an assessment of the probability of Pemvidutide's commercial success and the willingness of strategic partners to invest in scaling the business of Altimmune, Inc. (ALT) amid macroeconomic volatility.

Competing companies

Price-to-Projected Revenue Ratio Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc - Price-to-Projected Revenue Ratio|Corcept - Forward P/S Multiple|Market Cap to Expected Sales Ratio Rhythm Corp RYTM|Akero Therapeutics (AKRO) - Price-to-Projected Revenue Ratio|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake|Forward Price-to-Revenue Multiple Crinetics Pharmaceuticals, Inc. (CRNX)|Forward P/S Multiple NAMS|Forward P/S Multiple Soleno Therapeutics Corp (SLNO)|Price-to-Projected Revenue Ratio Amicus Therapeutics FOLD|89bio.com - Price-to-Projected Revenue Ratio|AGIO: Forward Price-to-Revenue Multiple|Structure Therapeutics Inc - Price to Expected Revenue Ratio|MDXG: Forward P/S Multiple|RZLT - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Lexicon Pharmaceuticals|Forward Price-to-Revenue Multiple mbxbio.com (MBX)|Price-to-Projected Revenue Ratio Aardvark Therapeutics (AARD)|Forward Price-to-Revenue Multiple Sagimet Biosciences, Inc. SGMT|BioAge Labs Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple Biomea Fusion Corp BMEA|QNCX - Price-to-Projected Revenue Ratio|GUTS (fractyl.com) - Market Cap to Projected Revenue|VTVT: Forward P/S Multiple|Market Cap to Future Revenue Ratio Agape ATP (ATPC)|Forward Price-to-Revenue Multiple PLUR|SYBX: Forward Price to Sales|Forward P/S Multiple LPCN|Market Cap to Expected Sales Ratio matinasbiopharma.com|Price-to-Projected Revenue Ratio Spruce Biosciences, Inc. SPRB|GLTO: Market Cap to Projected Revenue|Carmell Corp - Forward P/S Multiple|Lumos Therapeutics (LUMO) - Forward Price-to-Revenue Multiple|ONVO (Organovo Holdings, Inc.) - Forward Price-to-Revenue Multiple|RDUS - Market Cap to Expected Sales Ratio